ilmscore | Prediction Details
"In the biotech and diabetes biosimilar segments, the company is targeting 20 to 25% growth by doubling its capacity in the next 3 years."
By Groww | January 11, 2026 | Pending
From video
3 stocks with business turnaround from loss to profits 00:11:48 - 00:11:53
Interpreted Prediction
Wockhardt aims for 20-25% growth in its biotech and diabetes biosimilar segments by doubling capacity within the next 3 years (by January 2029).

Prediction Details

Topic
Wockhardt Limited

Comments

Be the first to share your thoughts.

Like this prediction?

Join to make your opinion count.